857267-04-0

Basic information

• Product Name: 1-isopropyl-1H-pyrazol-3-amine
• Synonyms: 1-isopropyl-1H-pyrazol-3-amine;1-(propan-2-yl)-1H-pyrazol-3-amine;1-Isopropylpyrazol-3-amine
• CAS NO: 857267-04-0
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17164
• Mol File: 857267-04-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 234.2±13.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.00±0.10(Predicted)
• CAS DataBase Reference: 1-isopropyl-1H-pyrazol-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-isopropyl-1H-pyrazol-3-amine(857267-04-0)
• EPA Substance Registry System: 1-isopropyl-1H-pyrazol-3-amine(857267-04-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 857267-04-0(Hazardous Substances Data)

Usage

General Description

1-Isopropyl-1H-pyrazol-3-amine is a chemical compound with the molecular formula C6H11N3. It is a pyrazole derivative with an isopropyl group attached to the amino group. 1-isopropyl-1H-pyrazol-3-amine is commonly used in the pharmaceutical industry as a building block in the synthesis of various biologically active compounds. It has also been studied for its potential therapeutic properties, including antifungal and antimicrobial activities. Additionally, 1-isopropyl-1H-pyrazol-3-amine has been investigated for its potential use as an inhibitor of certain enzymes and as a potential anti-inflammatory agent. Overall, this chemical compound has shown promise for a variety of potential applications in the fields of medicine and biotechnology.

Upstream product

• 70629-60-6 isopropylhydrazine hydrochloride 
• 920-37-6 2-Chloroacrylonitrile 
• 2257-52-5 N-isopropylhydrazine 
• 1003012-75-6 1-isopropyl-3-nitro-1H-pyrazole 

Downstream Products

• 871656-88-1 3-[((1S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-methylethyl)oxy]-5-hydroxy-N-[1-(1-methylethyl)-1H-pyrazol-3-yl]benzamide 
• 1696838-10-4 1-isopropyl-1H-pyrazole-3-sulfonamide 
• 911434-15-6 3-[2-(2-aminopyrimidin-5-yl)ethynyl]-N-(1-propan-2-ylpyrazol-3-yl)-benzamide 
• 871656-89-2 3-[((1S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-methylethyl)oxy]-N-[1-(1-methylethyl)-1H-pyrazol-3-yl]-5-[(phenylmethyl)oxy]benzamide 

Relevant articles and documents

NOVEL PROCESSES

The present invention relates to processes of preparing N- ((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H- pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

NLRP3 INHIBITORS

The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.